US Article late yesterday on LCD14 Jun 2024 08:09
The market hasn't picked up on this news yet, I expect next week and to the end of June the news will start to dawn on the market.
This from the news outlet 360dx:
National Government Services: Renalytix's KidneyIntelX and KidneyIntelX.dkd
National Government Services released a final LCD this week aligned with its draft LCD covering Renalytix's KidneyIntelX and KidneyIntelX.dkd tests once in a patient's lifetime. The assays are covered if the results are used to facilitate therapeutic prognostic decision-making in the medical management of a selected patient population. They are also covered when the results are used to determine the risk of progressive decline in kidney function in patients older than 21 with Type 2 diabetes and existing early-stage chronic kidney disease if the test is ordered by the treating physician or qualified non-physician practitioner.
The test must be performed in a CLIA-certified laboratory qualified to perform high-complexity testing and the reason for the test must be documented by the treating practitioner and demonstrate that the test is medically reasonable and necessary.
The assays are not covered for patients with estimated glomerular filtration rates lower than 30 or above 60 without albuminuria, patients with end-stage renal disease or those on renal recovery treatments, pregnant patients, patients who are currently hospitalized, or those taking etanercept.
The tests are also not covered as screening or standalone diagnostics.
The final LCD goes into effect on Aug. 1.